Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma AR | NSE | Salute | Prodotti farmaceutici | 4,58 Bln INR | 44,1x | 1,88 | 1.910,35 INR | 1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -3,1% Ribasso | Fai l’upgrade a Pro+ | |
Sun Pharma Advanced Research | BSE | Salute | Prodotti farmaceutici | 4,58 Bln INR | 44,1x | 1,88 | 1.915 INR | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -4,6% Ribasso | Fai l’upgrade a Pro+ | |
Divis Laboratories | NSE | Salute | Prodotti farmaceutici | 1,60 Bln INR | 95,6x | 7,32 | 6.022,25 INR | -0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -21,4% Ribasso | Fai l’upgrade a Pro+ | |
Divis Laboratories | BSE | Salute | Prodotti farmaceutici | 1,60 Bln INR | 95,6x | 7,32 | 6.035 INR | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -20,8% Ribasso | Fai l’upgrade a Pro+ | |
Cipla | NSE | Salute | Prodotti farmaceutici | 1,25 Bln INR | 29,1x | 0,78 | 1.551,70 INR | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,1% Rialzo | Fai l’upgrade a Pro+ | |
Cipla | BSE | Salute | Prodotti farmaceutici | 1,25 Bln INR | 29,1x | 0,78 | 1.553,45 INR | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,3% Rialzo | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 67,3x | 1,86 | 3.438,40 INR | 1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,7% Ribasso | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 67,3x | 1,86 | 3.449,50 INR | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,4% Ribasso | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | BSE | Salute | Prodotti farmaceutici | 1,12 Bln INR | 20,3x | 1,13 | 6.756 INR | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,5% Ribasso | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | NSE | Salute | Prodotti farmaceutici | 1,12 Bln INR | 20,3x | 1,13 | 6.741,10 INR | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,4% Ribasso | Fai l’upgrade a Pro+ | |
Mankind Pharma | BSE | Salute | Prodotti farmaceutici | 1,08 Bln INR | 40,9x | 1,74 | 2.644 INR | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -10,2% Ribasso | Fai l’upgrade a Pro+ | |
Mankind Pharma | NSE | Salute | Prodotti farmaceutici | 1,08 Bln INR | 40,9x | 1,74 | 2.647,20 INR | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -10,1% Ribasso | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | BSE | Salute | Prodotti farmaceutici | 1,03 Bln INR | 24,7x | 0,39 | 1.022,25 INR | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,5% Rialzo | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | NSE | Salute | Prodotti farmaceutici | 1,03 Bln INR | 24,7x | 0,39 | 1.022,45 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 12,7% Rialzo | Fai l’upgrade a Pro+ | |
Lupin | NSE | Salute | Prodotti farmaceutici | 994,62 Mrd INR | 44x | 0,34 | 2.179,70 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,4% Ribasso | Fai l’upgrade a Pro+ | |
Lupin | BSE | Salute | Prodotti farmaceutici | 994,62 Mrd INR | 44x | 0,34 | 2.185 INR | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,7% Ribasso | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | BSE | Salute | Prodotti farmaceutici | 854,45 Mrd INR | 24,5x | 0,32 | 1.474,30 INR | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,1% Rialzo | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | NSE | Salute | Prodotti farmaceutici | 854,45 Mrd INR | 24,5x | 0,32 | 1.472,70 INR | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,2% Rialzo | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd BO | BSE | Salute | Prodotti farmaceutici | 735,71 Mrd INR | 35,6x | 0,45 | 6.152,85 INR | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1% Ribasso | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd | NSE | Salute | Prodotti farmaceutici | 735,71 Mrd INR | 35,6x | 0,45 | 6.132,75 INR | 1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,1% Ribasso | Fai l’upgrade a Pro+ | |
Abbott India Ltd | BSE | Salute | Prodotti farmaceutici | 617,29 Mrd INR | 50x | 2,49 | 29.201 INR | 2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,1% Ribasso | Fai l’upgrade a Pro+ | |
Abbott India Ltd | NSE | Salute | Prodotti farmaceutici | 617,29 Mrd INR | 50x | 2,49 | 29.209,55 INR | 3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,8% Rialzo | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 490,77 Mrd INR | -37,4x | 0,05 | 1.738,45 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -7% Ribasso | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 490,77 Mrd INR | -37,4x | 0,05 | 1.739,45 INR | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2% Ribasso | Fai l’upgrade a Pro+ | |
GSK Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 455,67 Mrd INR | 69,5x | 28,39 | 2.659,30 INR | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,3% Rialzo | Fai l’upgrade a Pro+ | |
GSK Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 455,67 Mrd INR | 69,5x | 28,39 | 2.683 INR | 1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,9% Rialzo | Fai l’upgrade a Pro+ | |
IPCA Laboratories | NSE | Salute | Prodotti farmaceutici | 417,97 Mrd INR | 72,7x | 4,17 | 1.649,85 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -14% Ribasso | Fai l’upgrade a Pro+ | |
IPCA Laboratories | BSE | Salute | Prodotti farmaceutici | 417,97 Mrd INR | 72,7x | 4,17 | 1.648,40 INR | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -13,9% Ribasso | Fai l’upgrade a Pro+ | |
Ajanta Pharma Ltd | NSE | Salute | Prodotti farmaceutici | 400,12 Mrd INR | 47x | 1,26 | 3.199,55 INR | -1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -15,2% Ribasso | Fai l’upgrade a Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Salute | Prodotti farmaceutici | 400,12 Mrd INR | 47x | 1,26 | 3.182,35 INR | -1,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -13,3% Ribasso | Fai l’upgrade a Pro+ |